NFKB1 and glioma: While DEPDC1 has not been studied in meningioma, it is a known regulator of NFkB signaling and is overexpressed in multiple cancers such as glioma, breast cancer, and nasopharyngeal cancer, having been proposed as a potential therapeutic target in each28–30.